BioCentury
ARTICLE | Company News

Intellikine, Takeda deal

January 2, 2012 8:00 AM UTC

Takeda will acquire cancer company Intellikine for $190 million up front and up to $120 million in milestones. Takeda will gain Intellikine's INK128, an inhibitor of mammalian target of rapamycin co...